Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$17.46 USD

17.46
4,274,858

-0.21 (-1.19%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $17.41 -0.05 (-0.29%) 5:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 15% (39 out of 252)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View

Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance

Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.

Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down

Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.

Kinjel Shah headshot

Teva (TEVA) Beats on Q1 Earnings, Misses Sales, Shares Down

Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Shares decline in pre-market trading.

Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut

Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.

Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.14, marking a +0.93% move from the previous day.

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.

Allergan Falls as Supreme Court Dismisses Restasis Litigation

Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca

Kinjel Shah headshot

Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU

Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.

Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.

Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe

Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.

Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.

Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $16.64, marking a +0.79% move from the previous day.

BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up

BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.

Insys Plunges on Auditor's Concern About Insufficient Funds

Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

Allergan Announces FDA Acceptance of Migraine Candidate NDA

Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.78, marking a +0.19% move from the previous day.

Lilly's Emgality Gets FDA Priority Review for Cluster Headache

Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.

Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down

Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.